The Interleukin 1 Alpha pipeline drugs market research report outlays comprehensive information on the Interleukin 1 Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 1 Alpha pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Cardiovascular, and Gastrointestinal which include the indications Oncology, Multiple Myeloma (Kahler Disease), Rheumatoid Arthritis, Unspecified Immunological Disorders, Myocardial Infarction, Atherosclerosis, Ulcerative Colitis, and Crohn’s Disease (Regional Enteritis). It also reviews key players involved in Interleukin 1 Alpha targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 1 Alpha pipeline targets constitutes close to 12 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 3, 1, 2, 4, and 1 respectively.
Interleukin 1 Alpha overview
Interleukin-1 alpha (IL1A), also known as hematopoietin 1, is a cytokine of the interleukin 1 family that in humans is encoded by the IL1A gene. The protein encoded by this gene is a member of the interleukin 1 cytokine family. This cytokine is a pleiotropic cytokine involved in various immune responses, inflammatory processes, and hematopoiesis. This cytokine is produced by monocytes and macrophages as a proprotein, which is proteolytically processed and released in response to cell injury, and thus induces apoptosis.
For a complete picture of Interleukin 1 Alpha’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
